8-K

                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8-K


                         CURRENT REPORT

             Pursuant to Section 13 or 15(d) of the

                 Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 13, 2002


                 COMPETITIVE TECHNOLOGIES, INC.
     (Exact name of registrant as specified in its charter)



Delaware                 1-8696                   36-2664428
(State or other          (Commission File         (IRS Employer
jurisdiction             Number)                  Identification No.
of incorporation)



1960 Bronson Road, Fairfield, Connecticut         06824
(Address of principal executive offices)         (Zip Code)



Registrant's  telephone number, including area code
(203)  255-6044


1960 Bronson Road, Fairfield, Connecticut 06430

(Former name or former address, if changed since last report)


Item 5.  Other Events and Regulation FD Disclosure.

     On August 13, 2002, the United States District Court judge
for the District of Colorado awarded approximately $54 million,
plus certain interest from January 1, 2002, to the University of
Colorado Foundation and other plaintiffs in the MaternaTM patent
infringement litigation.  As a result of its contract with the
University of Colorado Foundation, Competitive Technologies, Inc.
(CTT) shares 18.2% of damages after attorneys' fees.  If this
judgment is not modified or appealed, CTT's share would be
approximately $6 million plus its proportionate share of
interest.

     Since the defendant may appeal this judgment, CTT is unable
to predict when this lawsuit will finally be settled or when it
will receive its share of damages finally awarded, if any.  CTT
has recorded no potential judgment proceeds in its financial
statements to date.

     (See discussion of MaternaTM Litigation in Note 6 to CTT's
Condensed Financial Statements in its report on Form 10-Q for the
quarterly period ended April 30, 2002, for further information
related to this lawsuit.)



Item 7.  Financial Statements and Exhibits.

  (c)  Exhibits.                                           Page

       99.1 Registrant's press release dated
               August 14, 2002                             3-4


                           Signatures

      Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.


                                   COMPETITIVE TECHNOLOGIES, INC.
                                   Registrant


Date:  August 16, 2002             S/ Frank R. McPike, Jr.
                                   By:  Frank R. McPike, Jr.

                                   Executive Vice President,
                                   Chief Financial Officer and
                                   Authorized Signer

EX-99.1

                                                           Exhibit 99.1



          CTT CLIENTS AWARDED OVER $54 MILLION AGAINST WYETH
                         IN MATERNA LITIGATION

                    CTT to Receive About $6 Million

Fairfield, CT (August 14, 2002): Competitive Technologies, Inc. (AMEX:
CTT) announced today that U.S. Senior District Court Judge John Kane of
the US District Court for the District of Colorado yesterday issued a
$54 million patent infringement judgment for fraud and unjust
enrichment against Wyeth's (NYSE: WYE) American Cyanamid Co. unit, and
in favor of CTT's client, the University of Colorado.

The litigation involves a prenatal vitamin supplement marketed by
Cyanamid under the MaternaTM name. A preliminary opinion issued in July
2000 found that Drs. Robert H. Allen and Paul A. Seligman, CTT's
clients at the University of Colorado are the sole inventors of the
improved formulation of the prenatal vitamin supplement.

In the opinion Judge Kane stated, "I again find beyond a reasonable
doubt that Cyanamid's clandestine and deceptive conduct relating to the
application for and issuance of the '634 Patent, together with its
exploitation of the doctors for its own gain, was attended by
circumstances of fraud, malice and willful and wanton misconduct and
that Drs. Allen and Seligman are entitled to an award of exemplary
damages."

Judge Kane indicated that the University and the citizens of Colorado
are entitled to equitable relief and exemplary damages in the form of a
disgorgement of Cyanamid's profits attributable to the exclusivity
rights wrongfully secured and enforced against (Cyanamid's)
competitors. CTT will receive 18.2% of the net proceeds, after attorney
fees, recovered from Wyeth in this $54 million award.

"We are pleased that the Court has found in favor of the University,
the citizens of Colorado and the inventors in this long-standing
litigation," said John B. Nano, President and CEO of CTT. "This
judgment is the eighth consecutive successful enforcement achieved by
CTT for its clients and shareholders."

CTT hopes that Wyeth will not appeal this decision since the issue of
conduct had already been appealed and the egregious conduct was
reaffirmed by Judge Kane. CTT believes that any appeal from this second
judgment could reflect current Wyeth management's lack of understanding
of the facts of this case. CTT is hopeful, that in the light of other
high-profile corporate scandals, Wyeth senior management will step
forward and take the morally correct path. CTT believes that this is an
era when corporate America needs to stand up for what is right and
moral, and Wyeth owes justice to the citizens of Colorado, the
University and the professors.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a global leader in
identifying, developing and commercializing innovative life sciences,
physical sciences, digital technologies and electronics. CTT's
specialized expertise and experience make it a valuable partner to
assist technology-rich universities, inventors and companies, of all
sizes, to maximize the value of their intellectual assets. Visit CTT's
website: www.competitivetech.net

Statements about the Company's future expectations, including
development and regulatory plans, and all other statements in this
document other than historical facts are "forward-looking statements"
within the meaning of applicable Federal Securities Laws and are not
guarantees of future performance. These statements involve risks and
uncertainties, including those set forth in Item 1 of the Company's
most recent Form 10-K and in CTT's filings with the SEC, and are
subject to change at any time. The Company's actual results could
differ materially from these forward-looking statements. The Company
undertakes no obligation to update publicly any forward-looking
statement.

Direct inquiries to:

Johnnie D. Johnson, Strategic IR, Inc.
E-mail:  jdjohnson@strategic-ir.com
Tel.  (212) 754-6565;
Fax  (212) 754-4333
E-mail:  ctt@competitivetech.net